BRCA1 and ovarian cancer: As we also found higher PAF-AH levels in BRCA1 mutation carriers and BRCA1 mutant ovarian cancer cells, we conclude that PAF-AH upregulation might be relevant to counteract PAF and Wnt signaling, respectively.